Determination of Safety, Efficacy, and Pharmacokinetics of GreenGene F in Previously Treated Patients 12 years of age or older Diagnosed with Severe Hemophilia A
Phase of Trial: Phase III
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs Beroctocog alfa (Primary) ; Moroctocog alfa
- Indications Haemophilia A
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors GC Pharma
- 02 Nov 2019 European Clinical Trials Database record reports the trial status as Prematurely Ended in UK.
- 02 Jan 2018 According to a GC Pharma media release, Green Cross Corporation rebrands itself to GC Pharma.
- 13 Oct 2016 Status changed from recruiting to suspended, according to a Green Cross media release.